<unk> , sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.
Lorlatinib
Tucatinib
Neratinib
Fostamatinib
Lapatinib
Ponatinib
Brigatinib
Selpercatinib